

Evaluation After a First Seizure in Adults

Kate Rowland, MD, MS, and Carl Earl Lambert Jr., MD, Rush University, Chicago, Illinois

Seizures are transient signs and symptoms of abnormal, excessive, or synchronous neuronal activity in the brain. Up to 10% of adults have a seizure during their lifetime, with increasing incidence in people older than 55 years. One-third of people have a recurrent seizure within one year of an initial unprovoked seizure. Acute symptomatic (provoked) seizures recur less often, especially when provoking factors are addressed. After confirming a probable seizure, evaluation focuses on identifying provoking factors such as tumor, metabolic derangement, infectious disease, stroke, traumatic brain injury, medications, or substance misuse. Magnetic resonance imaging with an epilepsy protocol and electroencephalography should be performed as soon as practical. Lumbar puncture is useful if intracranial infection is suspected. Immediate initiation of anti-seizure medication reduces seizure recurrence by 35% within the first two years. Recurrence rates between three and five years are similar between patients who start anti-seizure medication immediately after the first seizure and those who do not. Restoration of driving privileges varies by state. After a seizure, safety concerns should be addressed, such as the need for a safety companion when bathing or swimming and the risks of ladders and other hazards. (*Am Fam Physician*. 2022;105(5):507-513. Copyright © 2022 American Academy of Family Physicians.)

The International League Against Epilepsy (ILAE) defines seizures as a transient occurrence of signs or symptoms due to abnormal, excessive, or synchronous neuronal activity in the brain.¹ The ILAE categorizes seizures by the location of onset in the brain: focal, generalized, or unknown; they are subcategorized by the presence or absence of motor symptoms and loss of awareness.¹

In generalized onset seizures, abnormal electrical activity initiates throughout the brain. These types of seizures always include loss of awareness.¹ Focal onset seizures begin in one area of the brain, although they may generalize to involve the entire brain and may or may not include loss of awareness.¹ Motor symptoms can

include the classic tonic-clonic movements as well as myoclonus or atonic seizures.¹ Nonmotor symptoms of seizures may include emotional, sensory, and cognitive changes, or a lack of movement due to absence seizures.¹

Most people with a first seizure do not have epilepsy. Epilepsy usually requires two unprovoked seizures occurring at least 24 hours apart, but the diagnosis can be made based on a single unprovoked seizure with at least a 60% risk of a second seizure in the next 10 years, or in the setting of an epilepsy syndrome.² Determining the risk of a second seizure is an important part of the evaluation of the first seizure, although no formula exists to calculate risk and factors should be considered individually.

Epidemiology

The lifetime risk of having a seizure for an adult is up to 10%, although only 3% will be diagnosed with epilepsy.³ The incidence of a first seizure increases with age starting at approximately 55 years, with the highest risk in people older than 75 years.⁴

The rate of first seizures is higher in low-income countries than in the United States.⁵

CME This clinical content conforms to AAFP criteria for CME. See CME Quiz on page 458.

Author disclosure: No relevant financial relationships.

Patient information: A handout on this topic, written by the authors of this article, is available at <https://www.aafp.org/afp/2022/0500/p507-s1.html>.

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendation	Evidence rating	Comments
Evaluate patients for provoking factors after a first seizure. Provoking factors may be inflammatory, infectious, structural, toxic, or metabolic in nature and are found in 40% of first seizures. ¹⁰	C	Expert opinion based on epidemiologic studies
Use video-EEG monitoring during seizure-like activity to diagnose PNES, although up to 5% of patients diagnosed with PNES are eventually diagnosed with epilepsy. ^{23,24}	C	Expert opinion and a single clinical study
Look for findings most predictive of a seizure, such as tongue biting, head turning or twisting, limb jerking, and urinary incontinence when evaluating a patient for possible seizures. ¹⁶	B	Single study
Assess for history of medication or substance use that can provoke seizures through normal use, withdrawal, overdose, drug-drug interaction, or impaired metabolism due to comorbidities. ^{17,28,30-33}	C	Expert opinion, case reports, and case series
Order an MRI with epilepsy-specific protocol and EEG as soon as possible after a first unprovoked seizure. ^{9,18}	C	Expert opinion and guideline based on small to medium studies with inconsistent results
Recommend anti-seizure medications for patients with a high risk of seizure recurrence (e.g., patients with nighttime seizures, EEG abnormalities, history of brain insult, brain imaging abnormalities) after risks and benefits of treatment have been considered. ²¹	C	Guideline based on small clinical trials
Consider anti-seizure medications to reduce the risk of seizure recurrence by more than one-third at two years after a seizure. Recurrence rates are similar with or without medications after three years. ²¹	C	Guideline based on a systematic review of moderate-quality studies

EEG = electroencephalography; MRI = magnetic resonance imaging; PNES = psychogenic nonepileptic seizures.

A = consistent, good-quality patient-oriented evidence; **B** = inconsistent or limited-quality patient-oriented evidence; **C** = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to <https://www.aafp.org/afpsort>.

Low- and middle-income countries account for approximately 80% of epilepsy worldwide. This may be because of higher rates of risk factors for epilepsy, such as congenital conditions, intracranial infections, and traumatic brain injury.⁵ In high-income countries, first seizures are more common in people affected by social and economic deprivation.⁶ Worldwide, seizures are increased where there is inadequate access to health care.⁷

Types of Seizures

ACUTE SYMPTOMATIC (PROVOKED) SEIZURES

Acute symptomatic seizures, also known as provoked or situation-related seizures, are manifestations of an acute insult to the central nervous system. Stroke and central nervous system infection are the most identified provoking factors.⁸ Other provoking factors include metabolic derangements, such as electrolyte abnormalities,

or toxic effects of medications, alcohol, or drugs, including overdoses.⁹ Provoking factors may be infectious, inflammatory, metabolic, structural, or toxic in nature¹⁰ (Table 1¹¹⁻¹⁵).

Approximately 40% of first seizures are associated with provoking factors. The evaluation after a first seizure should focus on identifying these factors¹⁰ (Figure 1^{3,7,16-20}). This allows for the treatment of an underlying condition, or an assessment of an increased risk of seizure recurrence, to reduce the risk of subsequent seizures.⁷

UNPROVOKED SEIZURES

Unprovoked, or idiopathic, seizures do not have an acute cause identified on evaluation. Unprovoked seizures are most common in younger people.⁸ Unprovoked seizures are more likely to recur than those with a provoking cause found on evaluation.⁹

FIRST SEIZURE IN ADULTS

Unprovoked seizures are divided into two categories: those with no known etiology, and those related to progressive, preexisting, or remote central nervous system injury. Unprovoked seizures with known etiologies include prior traumatic brain injury, congenital cerebral palsy, and remote central nervous system infection.²¹ Unlike in acute symptomatic seizures, the central nervous system insult does not occur within the same time frame as the seizure. Recurrence is more common in unprovoked seizures with known etiologies.²²

PSYCHOGENIC NONEPILEPTIC SEIZURES

Psychogenic nonepileptic seizures (PNES) are seizure-like symptoms without abnormal electrical activity in the brain. They have psychological origins and have also been called pseudoseizures. The diagnostic standard for PNES is video-electroencephalography (EEG) monitoring during typical seizure-like activity.²³

PNES does not rule out neurologic seizures, because PNES can coexist with neurologic seizures and epilepsy. In one study of more than 2,000 people with refractory epilepsy, 32% had PNES on video-EEG monitoring.²⁴ In the same study, 5% of people diagnosed with PNES had epilepsy, and 2% were diagnosed with both.²⁴

People with PNES commonly report negative health care experiences and are more likely than patients with epilepsy to have a mental health diagnosis, but both groups are similar in sex distribution and age at diagnosis.^{25,26} PNES treatment requires interdisciplinary care that includes effective mental health care and continuity of care. Cognitive behavior therapy may be more effective than usual care at reducing seizure-like activity in the short term.²⁷ Patients may experience fear of not being taken seriously if they are perceived to have a psychiatric condition instead of a neurologic one, which can interfere with treatment effectiveness.²⁶

Evaluation

The clinical evaluation is focused on determining whether the patient had a seizure or experienced a seizure mimic, which includes syncope, migraine, or stroke without seizure.⁹ If a seizure is suspected, the evaluation focuses on identifying provoking factors. The evaluation does not vary based on seizure classification.

HISTORY

In addition to the patient's recollection of events, witness statements are essential. Seizure is more likely if tongue biting, head turning or twisting, limb jerking, or urinary incontinence occurred.

TABLE 1

Common Causes of Acute Symptomatic (Provoked) Seizures

Infectious	Metabolic	Structural
Encephalitis	Hepatic failure	Arteriovenous malformations
Meningitis	Hypocalcemia (serum calcium < 8.5 mg per dL [2.13 mmol per L])	Cerebrovascular accident
Neurocysticercosis	Hypoglycemia (blood glucose < 36 mg per dL [2 mmol per L]) or hyperglycemia (blood glucose > 450 mg per dL [24.98 mmol per L])	Intracranial lymphoma
Prion disease	Hypomagnesemia (serum magnesium < 1.2 mg per dL [0.49 mmol per L])	Neurosurgery
Toxoplasmosis	Hyponatremia (serum sodium < 110 mEq per L [110 mmol per L])	Primary or secondary brain tumor
Tuberculosis	Hypoxia	Traumatic brain injury
Inflammatory	Porphyria	Toxic
Celiac disease	Renal failure	Alcohol withdrawal
Hashimoto encephalitis		Prescribed medications (Table 2)
Other autoimmune conditions		Substance misuse (e.g., cocaine, phencyclidine [PCP])
Sarcoidosis		Other
Systemic lupus erythematosus		Sleep deprivation

Information from references 11-15.

Prodromal symptoms, such as déjà vu, mood changes, hallucinations, confusion, or post-event amnesia, also increase the likelihood of seizure. Factors that suggest diagnoses other than seizure

include chest pain, nausea, dyspnea, palpitations, and presyncopal symptoms such as lightheadedness, tunnel vision, and dizziness.^{7,16}

MEDICATION AND SUBSTANCE USE

Many medications can contribute to having a seizure; therefore, evaluation should include a comprehensive history of medication and substance use, including those recently started or stopped.²⁸ Common medications associated with an increased risk of seizure include bupropion (Wellbutrin), diphenhydramine (Benadryl), and tramadol.²⁹ Table 2 lists other medications associated with an increased risk of seizure.^{17,18,28,30-33} Seizures can be caused by use of or withdrawal from substances including alcohol, opioids, stimulants, and cocaine.¹⁷

PHYSICAL EXAMINATION


A complete neurologic examination should be conducted after the postictal period when the patient is alert and no longer disoriented to identify a neurologic provoking factor, such as lateralizing cortical deficits (i.e., unilateral weakness or aphasia).³⁴ Other provoking factors include signs of infection, cerebrovascular disease, or metabolic derangement.

LABORATORY EVALUATION

Although the value of laboratory analyses is uncertain, some can identify provoking factors. A complete blood count can suggest central nervous system infection. A comprehensive metabolic panel may indicate hyperglycemia, electrolyte disturbances, particularly hyponatremia, or renal or hepatic disease. Although a toxicology screen could indicate the presence of provoking drugs, evidence is insufficient to suggest screening all patients with a first seizure.¹⁸

No laboratory study can accurately diagnose a recent seizure, but a normal serum prolactin level may help rule out seizure in a patient with suspected PNES.³⁵ However, one study of patients undergoing continuous EEG

FIGURE 1



EEG = electroencephalography; MRI = magnetic resonance imaging.

Algorithm for the evaluation of suspected first seizure in adults.

*—A seizure is more likely with witnessed tongue biting, head turning, twisting movements, and urinary incontinence. Prodromal symptoms include déjà vu, mood changes, or hallucinations. Post-event confusion or amnesia also increases the likelihood of seizure. Symptoms such as chest pain, lightheadedness, tunnel vision, nausea, or palpitations suggest an alternate etiology.

Information from references 3, 7, and 16-20.

TABLE 2

Medications Associated With Increased Risk of Seizure**Analgesics**

Fentanyl
 Meperidine (Demerol)
 Morphine (epidural or intrathecally)
 Tramadol

Antihistamines

First-generation more likely than second-generation

Anti-infectives

Carbapenems
 Cephalosporins
 Isoniazid

Decongestants

Pseudoephedrine

Immunosuppressants

Cyclosporine (Sandimmune)
 Methotrexate (intravenously or intrathecally)
 Tacrolimus (Prograf [orally or intravenously])

Psychiatric

Antidepressants
 Bupropion (Wellbutrin)
 Trazodone
 Tricyclic antidepressants
 Venlafaxine
 Antipsychotics
 Chlorpromazine
 Clomipramine (Anafranil)
 Clozapine (Clozaril)
 Stimulants
 Atomoxetine (Strattera)

Miscellaneous

Baclofen (Lioresal)
 Lindane
 Theophylline
 Zolpidem (Ambien)

Note: Mechanism may be through therapeutic dose, abrupt withdrawal or discontinuation, overdose, drug-drug interaction, or impaired metabolism due to comorbidities (e.g., liver or kidney disease).

Information from references 17, 18, 28, and 30-33.

monitoring questioned its usefulness, because 25% of patients with nonepileptic seizures had an elevated prolactin level and 15% of patients with neurologic seizures did not.³⁶ Although serum prolactin level may be elevated after a seizure, other events cause similar elevations. In one study, prolactin was elevated in 60% of patients after vasovagal syncope and 78% of patients after seizure.³⁷

NEUROIMAGING

Up to 30% of patients with a first seizure have abnormalities on brain imaging.⁹ With a focal seizure, fever, persistent headache, neurologic deficit, acute head trauma, anticoagulant use, malignancy, or immunocompromise, immediate computed tomography is recommended.^{9,38}

Magnetic resonance imaging (MRI) using an epilepsy-specific protocol is indicated for patients

with a first nonfebrile seizure who do not have any evidence of provoking factors on initial workup, and it should be considered for all patients.^{9,18} An epilepsy-specific MRI protocol includes thin slices to improve sensitivity for lesions associated with epilepsy. Even if initial regular MRI imaging was performed, an epilepsy-specific MRI is recommended.^{3,9,19} If MRI is not available, computed tomography may be considered.

LUMBAR PUNCTURE

With fever, stiff neck, immunocompromise, or altered mental status, a lumbar puncture after normal initial imaging can demonstrate intracranial infection. In patients who are awake and alert and without signs, symptoms, or risk factors for infection, there is insufficient evidence for lumbar puncture.¹⁸

ELECTROENCEPHALOGRAPHY

EEG should be performed as soon as possible, ideally within 24 hours after an unprovoked seizure when the test is most likely to capture epileptiform activity.^{3,7,9,18} When initial EEG results are normal, a follow-up study, such as sleep-deprived EEG or prolonged ambulatory EEG, can capture epileptiform activity. It is recommended that these follow-up studies be completed as soon as possible, ideally within seven days.³⁹ The presence of EEG abnormalities nearly doubles seizure recurrence risk, which impacts the decision to treat.^{18,21}

EEG should be done only in patients whose clinical presentation is consistent with a possible seizure, such as witnessed tonic-clonic movements, a postictal period, and evidence of tongue biting or other indicative physical examination finding. In approximately one-half of patients with a first seizure, an EEG abnormality is identified. EEG abnormalities are also found in 4% of patients without seizure.⁷ EEG cannot rule out seizure in a patient who had unwitnessed loss of consciousness. Normal EEG results do not eliminate epilepsy because up to 10% of patients with epilepsy initially have a normal EEG.⁷

Outpatient Evaluation

Patients who are clinically stable and lack a clear provoking factor can be safely discharged from the emergency department.²⁰ Admission for EEG and neuroimaging is warranted if outpatient studies cannot be completed in a timely manner.

Prevention of Recurrent Seizures

About one-third of adults experience a second seizure within one year of an unprovoked seizure, and nearly one-half experience a second seizure within two years.²¹ The risk factors of nighttime seizure, EEG abnormalities, abnormal brain imaging, and history of brain insult more than double the risk of recurrent seizure.²¹

The decision to start anti-seizure medication is based on assessment of the patient's risk of recurrent seizure. The patient's estimated risk of recurrence based on factors or findings on workup can be provided with the medication risks and benefits for shared decision-making. Declining medication is reasonable, especially without risk factors.

Medications reduce the absolute risk of seizure recurrence by 35% within the first two years of treatment with immediate initiation of anti-seizure medications after the first seizure.²¹ The benefit of anti-seizure medication wanes over time. Patients who do not start treatment with anti-seizure medication have equivalent seizure rates between three and five years as patients who started anti-seizure medication after the first seizure.^{21,40} Despite early seizure reduction, quality of life is not improved with medication.²¹ Anti-seizure medications do not affect mortality after a first or subsequent seizure.^{40,41} Up to 31% of patients report adverse effects from anti-seizure medications.²¹ Most adverse effects are mild and reversible but include cognitive changes, coordination difficulty, somnolence, and personality changes.^{21,42}

Patients may choose medication to shorten driving restrictions, because driving privileges often require a seizure-free period. Patients taking anti-seizure medication are more likely to be driving after two years.⁴³ Anti-seizure medication selection is discussed in a previous article on epilepsy treatment (<https://www.aafp.org/afp/2017/0715/p87.html>).

Safety Counseling

Each state has its own laws regarding driving restrictions and physician reporting. Some states restrict driving for 12 months after being seizure free, whereas others allow driving to be resumed at the discretion of the treating clinician. The Epilepsy Foundation summarizes requirements for each state at <https://www.epilepsy.com/driving-laws>.

Patients with a first seizure should be counseled on avoiding hazardous situations in case

of a subsequent seizure. Physical hazards such as ladders and sharp objects should be avoided, and a safety companion is recommended when swimming or bathing.⁷

This article updates previous articles on this topic by Adams and Knowles⁴⁴; and Wilden and Cohen-Gadol.⁴⁵

Data Sources: We searched PubMed for clinical trials and reviews using keywords "seizure" "first seizure" and "seizure NOT febrile NOT epilepsy." We searched the Cochrane Database of Systematic Reviews, the Agency for Healthcare Research and Quality, the U.S. Preventive Services Task Force, Essential Evidence Plus including InfoPOEMs, and UpToDate. Also searched were the American Academy of Neurology, American College of Emergency Physicians, and the International League Against Epilepsy sites for clinical practice guidelines, as well as the Epilepsy Foundation site. Search dates: February 9, 2021; April 12, 2021; April 14, 2021; January 12, 2022

The authors thank Angelica Lee, MD, FAAN, for her suggestions and assistance with the algorithm.

The Authors

KATE ROWLAND, MD, MS, FAAFP, is the vice chair for education and an associate professor in the Department of Family Medicine at Rush University, Chicago, Ill. At the time this article was written she was a core faculty member at the Rush Copley Family Medicine Residency, Aurora, Ill.

CARL EARL LAMBERT Jr., MD, FAAFP, is director of the Rush Family Medicine Leadership Program and an assistant professor in the Department of Family Medicine at Rush University.

Address correspondence to Kate Rowland, MD, MS, FAAFP, Rush University, 1645 W. Jackson, #302, Chicago, IL 60612 (email: Kathleen_rowland@rush.edu). Reprints are not available from the authors.

References

1. Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE Commission for Classification and Terminology. *Epilepsia*. 2017;58(4):522-530.
2. Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE official report: a practical clinical definition of epilepsy. *Epilepsia*. 2014;55(4):475-482.
3. Pohlmann-Eden B, Beghi E, Camfield C, et al. The first seizure and its management in adults and children. *BMJ*. 2006;332(7537):339-342.
4. Hauser WA, Annegers JF, Rocca WA. Descriptive epidemiology of epilepsy: contributions of population-based studies from Rochester, Minnesota. *Mayo Clin Proc*. 1996; 71(6):576-586.
5. World Health Organization. Epilepsy. June 20, 2019. Accessed April 12, 2021. <https://www.who.int/news-room/fact-sheets/detail/epilepsy>

6. Heaney DC, MacDonald BK, Everitt A, et al. Socioeconomic variation in incidence of epilepsy: prospective community based study in south east England. *BMJ*. 2002; 325(7371):1013-1016.
7. Angus-Leppan H. First seizures in adults [published correction appears in *BMJ*. 2014;348:g2977]. *BMJ*. 2014;348: g2470.
8. Kaur S, Garg R, Aggarwal S, et al. Adult onset seizures: clinical, etiological, and radiological profile. *J Family Med Prim Care*. 2018;7(1):191-197.
9. Gavvala JR, Schuele SU. New-onset seizure in adults and adolescents: a review. *JAMA*. 2016;316(24):2657-2668.
10. Hauser WA, Beghi E. First seizure definitions and worldwide incidence and mortality. *Epilepsia*. 2008;49(suppl 1):8-12.
11. Beghi E, Carpio A, Forsgren L, et al. Recommendation for a definition of acute symptomatic seizure. *Epilepsia*. 2010; 51(4):671-675.
12. Devinsky O, Schein A, Najjar S. Epilepsy associated with systemic autoimmune disorders. *Epilepsy Curr*. 2013;13(2): 62-68.
13. Kumlien E, Lundberg PO. Seizure risk associated with neuroactive drugs: data from the WHO adverse drug reactions database. *Seizure*. 2010;19(2):69-73.
14. Misra UK, Kalita J. Management of provoked seizure. *Ann Indian Acad Neurol*. 2011;14(1):2-8.
15. Nardone R, Brigo F, Trinka E. Acute symptomatic seizures caused by electrolyte disturbances. *J Clin Neurol*. 2016; 12(1):21-33.
16. Sheldon R, Rose S, Ritchie D, et al. Historical criteria that distinguish syncope from seizures. *J Am Coll Cardiol*. 2002; 40(1):142-148.
17. Therapeutic Research Center. Meds that increase seizure risk. *Pharmacists' Letter*. August 2017.
18. Krumholz A, Wiebe S, Gronseth G, et al. Practice parameter: evaluating an apparent unprovoked first seizure in adults (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. *Neurology*. 2007;69(21):1996-2007.
19. Bernasconi A, Cendes F, Theodore WH, et al. Recommendations for the use of structural magnetic resonance imaging in the care of patients with epilepsy: a consensus report from the International League Against Epilepsy Neuroimaging Task Force. *Epilepsia*. 2019;60(6):1054-1068.
20. Huff JS, Melnick ER, Tomaszewski CA, et al; American College of Emergency Physicians. Clinical policy: critical issues in the evaluation and management of adult patients presenting to the emergency department with seizures [published correction appears in *Ann Emerg Med*. 2017; 70(5):758]. *Ann Emerg Med*. 2014;63(4):437-447.e15.
21. Krumholz A, Wiebe S, Gronseth GS, et al. Evidence-based guideline: management of an unprovoked first seizure in adults: report of the Guideline Development Subcommittee of the American Academy of Neurology and the American Epilepsy Society. *Epilepsy Curr*. 2015;15(3):144-152.
22. Rizvi S, Ladino LD, Hernandez-Ronquillo L, et al. Epidemiology of early stages of epilepsy: risk of seizure recurrence after a first seizure. *Seizure*. 2017;49:46-53.
23. Kanemoto K, LaFrance WC Jr., Duncan R, et al. PNES around the world: where we are now and how we can close the diagnosis and treatment gaps-an ILAE PNES Task Force report [published correction appears in *Epilepsia Open*. 2019;4(1):219]. *Epilepsia Open*. 2017;2(3):307-316.
24. Martin R, Burneo JG, Prasad A, et al. Frequency of epilepsy in patients with psychogenic seizures monitored by video-EEG. *Neurology*. 2003;61(12):1791-1792.
25. Szaflarski JP, Ficker DM, Cahill WT, et al. Four-year incidence of psychogenic nonepileptic seizures in adults in Hamilton County, OH. *Neurology*. 2000;55(10):1561-1563.
26. Rawlings GH, Reuber M. What patients say about living with psychogenic nonepileptic seizures: a systematic synthesis of qualitative studies. *Seizure*. 2016;41:100-111.
27. Goldstein LH, Chalder T, Chigwedere C, et al. Cognitive-behavioral therapy for psychogenic nonepileptic seizures: a pilot RCT. *Neurology*. 2010;74(24):1986-1994.
28. Chen H, Albertson TE, Olson KR. Treatment of drug-induced seizures. *Br J Clin Pharmacol*. 2016;81(3):412-419.
29. Thundiyil JG, Kearney TE, Olson KR. Evolving epidemiology of drug-induced seizures reported to a poison control center system. *J Med Toxicol*. 2007;3(1):15-19.
30. Zagaria ME. Common causes of drug-induced seizures. *US Pharm*. 2010;35(1):20-23.
31. Hill T, Coupland C, Morriss R, et al. Antidepressant use and risk of epilepsy and seizures in people aged 20 to 64 years: cohort study using a primary care database. *BMC Psychiatry*. 2015;15:315.
32. Lacroix C, Kheloufi F, Montastruc F, et al. Serious central nervous system side effects of cephalosporins: a national analysis of serious reports registered in the French Pharmacovigilance Database. *J Neurol Sci*. 2019;398:196-201.
33. Pisani F, Oteri G, Costa C, et al. Effects of psychotropic drugs on seizure threshold. *Drug Saf*. 2002;25(2):91-110.
34. Annegers JF, Shirts SB, Hauser WA, et al. Risk of recurrence after an initial unprovoked seizure. *Epilepsia*. 1986;27(1): 43-50.
35. Chen DK, So YT, Fisher RS. Use of serum prolactin in diagnosing epileptic seizures: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology [last reaffirmed January 2019]. *Neurology*. 2005;65(5):668-675.
36. Abubakr A, Wambacq I. Diagnostic value of serum prolactin levels in PNES in the epilepsy monitoring unit. *Neurol Clin Pract*. 2016;6(2):116-119.
37. Lusić I, Pintarić I, Hozo I, et al. Serum prolactin levels after seizure and syncopal attacks. *Seizure*. 1999;8(4):218-222.
38. Lee RK, Burns J, Ajam AA, et al.; Expert Panel on Neurological Imaging. ACR appropriateness criteria: seizures and epilepsy. *J Am Coll Radiol*. 2020;17(5S):S293-S304.
39. Debicki DB. Electroencephalography after a single unprovoked seizure. *Seizure*. 2017;49:69-73.
40. Leone MA, Giussani G, Nevitt SJ, et al. Immediate antiepileptic drug treatment, versus placebo, deferred, or no treatment for first unprovoked seizure. *Cochrane Database Syst Rev*. 2021;(5):CD007144.
41. Leone MA, Vallalta R, Solari A, et al.; FIRST Group. Treatment of first tonic-clonic seizure does not affect mortality: long-term follow-up of a randomised clinical trial. *J Neurol Neurosurg Psychiatry*. 2011;82(8):924-927.
42. Perucca P, Gilliam FG. Adverse effects of antiepileptic drugs [published correction appears in *Lancet Neurol*. 2012;11(9):746]. *Lancet Neurol*. 2012;11(9):792-802.
43. Jacoby A, Gamble C, Doughty J, et al.; Medical Research Council MESS Study Group. Quality of life outcomes of immediate or delayed treatment of early epilepsy and single seizures. *Neurology*. 2007;68(15):1188-1196.
44. Adams SM, Knowles PD. Evaluation of a first seizure. *Am Fam Physician*. 2007;75(9):1342-1347. Accessed October 21, 2021. <https://www.aafp.org/afp/2007/0501/p1342.html>
45. Wilden JA, Cohen-Gadol AA. Evaluation of first nonfebrile seizures. *Am Fam Physician*. 2012;86(4):334-340. Accessed October 21, 2021. <https://www.aafp.org/afp/2012/0815/p334.html>